• Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study | Morningstar

    Source: Buzz FX / 09 May 2025 03:36:28   America/Los_Angeles


    Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study
    Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for
    Read more...
Share on,